Like IL-6, OSM feed-forward signaling is observed in aggressive cancers with limited-therapeutic options, including glioblastoma (GBM), non-small cell lung carcinoma (NSCLC), PDAC, and triple negative breast cancer (TNBC) [107,108,109,110,111]. The gene discussed is IL6; the disease is non-small cell lung carcinoma.